Michael Baker

Company: Arovella Therapeutics

Job title: CEO

Seminars:

Unlocking the Groundbreaking Potential of iNKT Cells for Allogeneic Cancer Therapy 2:00 pm

Arovella is developing its novel iNKT cell therapy platform to develop allogenic cell therapies to treat cancer. Arovella is initially targeting haematological malignancies with its lead product ALA-101. Through a strategic collaboration with Imugene, Arovella will use ALA-101 to target solid tumours. Arovella is also developing its DKK1- CARiNKT cells to target multiple myeloma and…Read more

day: Day Two